Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Germonpré, P" or (type exact bookEditor and editor="Germonpré, P")

Add to list
- Journal Article
- A1
- open access
Changing preferences for information and participation in the last phase of life: a longitudinal study among newly diagnosed advanced lung cancer patients

Koen Pardon (UGent) , Reginald Deschepper (UGent) , Robert Vander Stichele (UGent) , Jan Bernheim, Freddy Mortier (UGent) , Nathalie Bossuyt, D Schallier, P Germonpré, D Galdermans, W Van Kerckhoven, et al.

(2012) SUPPORTIVE CARE IN CANCER. 20(10). p.2473-2482
Add to list
- Conference Paper
- C3
Pemetrexed (P) and Cisplatin (C) as either Induction (IC) or Adjuvant (AC) Chemotherapy in stage IB-II Non-Small Cell Lung Cancer (NSCLC): A randomized phase 2 study (EORTC 08051)

Jan Van Meerbeeck (UGent) , P Germonpre, Frank Vermassen (UGent) , J Welch and PE Van Schil

(2009) JOURNAL OF THORACIC ONCOLOGY. 4(9). p.S791-S791
Add to list
- Conference Paper
- C3
Soluble mesothelin as a monitoring tool in the management of malignant mesothelioma patients

Kevin Hollevoet (UGent) , E Kellen, K Nackaerts, L Bosquee, P Germonpre, Joris Delanghe (UGent) , C Legrand and Jan Van Meerbeeck (UGent)

(2009) JOURNAL OF THORACIC ONCOLOGY. 4(9). p.S761-S762
Add to list
- Conference Paper
- C3
Validation of soluble mesothelin: design and preliminary results of a Belgian multicentric observational study

Kevin Hollevoet (UGent) , E Kellen, K Nackaerts, J Thimpont, P Germonpre, P De Vuyst, L Bosquee, Joris Delanghe (UGent) , C Legrand and Jan Van Meerbeeck (UGent)

(2009) JOURNAL OF THORACIC ONCOLOGY. 4(9). p.S345-S345
Add to list
- Conference Paper
- C3
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor as biomarkers of mesothelioma

Kevin Hollevoet (UGent) , K Nackaerts, J Thimpont, P Germonpre, P De Vuyst, L Bosquee, C Legrand, K Yoshiro, Joris Delanghe (UGent) and Jan Van Meerbeeck (UGent)

(2009) EJC SUPPLEMENTS. 7(4). p.9-9

Academic Bibliography

Changing preferences for information and participation in the last phase of life: a longitudinal study among newly diagnosed advanced lung cancer patients

Pemetrexed (P) and Cisplatin (C) as either Induction (IC) or Adjuvant (AC) Chemotherapy in stage IB-II Non-Small Cell Lung Cancer (NSCLC): A randomized phase 2 study (EORTC 08051)

Soluble mesothelin as a monitoring tool in the management of malignant mesothelioma patients

Validation of soluble mesothelin: design and preliminary results of a Belgian multicentric observational study

Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor as biomarkers of mesothelioma

Contents

Support

Contact